CD200 baseline serum levels predict prognosis of chronic lymphocytic leukemia in Leukemia and Lymphoma
2021
AOU Città della Salute di Torino
Tipo pubblicazione
Conference Abstract
Autori/Collaboratori (17)Vedi tutti...
D'Arena G
Hematology, ASL Salerno, Vallo della Lucania, Italy
Laurenti L
Institute of Haematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
D'Agostino S
Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
et alii...
Abstract
Chronic lymphocytic leukemia (CLL) cells overexpress surface membrane CD200 and there is some evidence that the soluble ectodomain (sCD200) could be related to disease progression. However, very little is known about sCD200 prognostic significance. sCD200 was tested at diagnosis in 272 patients with CLL and 78 age and sex-matched healthy subjects using human CD200 (OX-2 membrane glycoprotein) ELISA kit (Wuhan Fine Biotech Co., Ltd., Wuhan, Hubei, China). CLL patients had a significantly higher concentration of sCD200 compared to controls (median, 1281 vs. 799 pg/ml; p=0.0002). In patients with CLL, sCD200 was significantly higher in those ?66 vs. <66 years old (median, 1560 vs. 1193 pg/ml; p=0.0001), in those with Binet stage C vs. A/B (2055 vs. 1274 pg/ml; p=0.0045), in those with unmutated vs. mutated IgVH (1601 vs. 1131 pg/ml; p<0.0001), and in those with unfavorable (del11q or del17p) vs. favorable (normal or del13q or tris12) FISH (1897 vs. 1239 pg/ml; p=0.0077). On the contrary, gender, bulky disease, whole blood cell or lymphocyte count, b-2-microglobulin serum levels, and presence of autoimmune complications did not significantly correlate with sCD200. The median value for CD200s concentration in the whole CLL cohort (1281 pg/ml) was selected as the cutoff to discriminate patients with low and high CD200s serum concentration. Median time-to-firsttreatment (TTFT) was shorter in patients with high sCD200 concentration (61 vs. 109 months; p<0.001). Finally, when patients were grouped according to sCD200?1281 or <1281 pg/ml, an impact on overall survival (OS) was also shown: median OS: 222 vs. 299 months, respectively; (p=0.005). A total of 152 patients in our cohort received CLL-directed treatment (chemotherapy or chemo-immunotherapy, n=123; anti-CD20 monoclonal antibody, n=3; targeted agent, n=26) and had response data available. Baseline sCD200 values appear to have an impact on response to therapy (p=0.0468), and this difference seems to increase
Se sei accreditato in BVS-P effettua l'accesso per utilizzare i nostri servizi.
DOI : 10.1080/10428194.2021.1995175
Keywords
bendamustine; beta 2 microglobulin; CD20 antibody; CD200 antigen; cyclophosphamide; endogenous compound; fludarabine; rituximab; trometamol; adult; cancer chemotherapy; cancer patient; cancer prognosis; cancer survival; China; chronic lymphatic leukemia; cohort analysis; complication; conference abstract; controlled study; drug therapy; ELISA kit; female; gender; human; human cell; human tissue; immunotherapy; lymphocyte; lymphocyte count; major clinical study; male; overall survival; prognosis; protein blood level; protein function; treatment response; univariate analysis;